Clinical Study on the Effect of CPAP on AF Recurrence After Catheter Ablation in Patients With AF and OSA
NCT Number: NCT06542263
Status: RECRUITING
Study Type: OBSERVATIONAL
Conditions: Atrial Fibrillation|Continuous Positive Airway Pressure|Obstructive Sleep Apnea|Recurrence|Observational Study
Interventions: DEVICE: CPAP
Sponsor: Second Affiliated Hospital of Soochow University
Sex: ALL
Age: ADULT, OLDER_ADULT
Enrollment: 224
Study Design: Observational Model: |Time Perspective: p
Start Date: 2024-08-09
Completion Date: 2026-08-01
Locations: The Second Affiliated Hospital of Soochow University, Suzhou, Jinagsu, 215004, China

Summary:
Atrial fibrillation (AF) is the most common sustained arrhythmia in clinical practice, significantly increasing the risks of death, stroke, heart failure, cognitive impairment, and dementia, thus severely impacting patients' quality of life. However, for AF patients with concomitant cardiovascular risk factors, particularly those with obstructive sleep apnea (OSA), the success rate of catheter ablation is significantly reduced. Continuous positive airway pressure (CPAP) is currently an effective treatment for OSA, effectively correcting nocturnal intermittent hypoxia and fragmented sleep caused by OSA. However, the effect of CPAP therapy on AF recurrence in patients with OSA undergoing catheter ablation remains controversial. Faced with conflicting research findings, our team recently conducted a meta-analysis (registration number CRD42023398588) to assess the impact of CPAP on AF recurrence post catheter ablation in patients with AF and OSA, suggesting that CPAP significantly reduces AF recurrence post catheter ablation (RR = 0.58, P \< 0.01). However, considering the limited number of included studies, potential bias risks, and confounding factors, our meta-analysis results await further confirmation through real-world studies by our team. Therefore, our team plans to conduct further research on the impact of CPAP on AF recurrence post catheter ablation in patients with moderate to severe OSA, aiming to provide clinical guidance for the treatment of AF in patients with moderate to severe OSA.

Primary Outcome Measures: AF recurrence after ablation, AF recurrence after ablation via Surface electrocardiogram and 24-hour dynamic electrocardiogram examination. If there are symptoms, seek medical attention at any time for electrocardiogram examination, At 3, 6, 9, and 12 months after AF ablation|AF burden after ablation AF burden after ablation AF burden after ablation, AF burden after ablation via 24-hour dynamic electrocardiogram examination AF burden after ablation via 24-hour dynamic electrocardiogram examinatio AF burden after ablation via 24-hour dynamic electrocardiogram examinatio, At 3, 6, 9, and 12 months after AF ablation
Secondary Outcome Measures: The recurrence of AF after combination with antiarrhythmic drugs, The recurrence of AF after combination with antiarrhythmic drugs via Surface electrocardiogram and 24-hour dynamic electrocardiogram examination. If there are symptoms, seek medical attention at any time for electrocardiogram examination, At 3, 6, 9, and 12 months after AF ablation|AF burden after combination with antiarrhythmic drugs, AF burden after combination with antiarrhythmic drugs via 24-hour dynamic electrocardiogram examinatio, At 3, 6, 9, and 12 months after AF ablation|SF-36, SF-36 with standard scores ranging from 0 to 100. The higher the score, the better the health status, At 3 and 12 months after AF ablation|Euro-QoL5D Survey Scoring, Euro-QoL5D survey questionnaire is between 0 and 100, with higher scores indicating better health status, At 3 and 12 months after AF ablation